Eagle said
“If approved it will be Europe's first approved 39 amino acid ACTH product . Synacthen and Cortrosyn are both 24 amino acids. The full amino acid chain ACTH has a few advantages over the shorter version such as being able to activate more melanocortin receptors and a stronger anti inflammatory response. “
This appears to my inexpert eyes to be significant.
What do the experts here think?
Is that close to mimicking the human version?
- Forums
- ASX - By Stock
- Ann: CLINUVEL advances NEURACTHEL Instant, EU filing mid-2026
CUV
clinuvel pharmaceuticals limited
Add to My Watchlist
3.92%
!
$12.26
Eagle said “If approved it will be Europe's first approved 39...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.